Ireland
--:--IST
Recruiting Observational

Safety and Normative Data With Neos™

NCT07258212 · tracked via the Priya Life Science Switzerland tracker
Sponsor
machineMD AG
Phase
Observational
Started
2024-03-07
Last updated
2025-12-02

Condition(s) studied

Neuro-Ophthalmology

Study summary

The goal of this clinical study is to collect standard data for the medical device neos™.

neos™ is a system that shows images and measures the resulting eye movements and pupil size.

Collecting standard data involves three steps. First it is checked if neos™ eye-tracking works well. Eye-tracking means recording where a person is looking. After that it is checked if participants look at the images shown in neos™ as planned. Finally the eye movements and the pupil size are measured. This is done in healthy volunteers including children and persons with eye and brain problems.

Participants in the study will wear a virtual reality headset. The screens in the headset will show different images. Cameras in the headset will record eye movements and pupil size. This will take about 15 minutes. During these 15 minutes the investigator looks at the following behaviors of the participants eyes:

* Where are the eyes looking
* How do the pupils react to light and darkness
* How do the eyes move
* How much can the participant see from the corner of their eyes
* How well are the eyes working together

Eligibility

Sex
ALL
Min age
3 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria Healthy Volunteers: * Age \> 3 * Informed consent by participant and/or legal representative documented per signature * Snellen visual acuity ≥ +0.1 LogMAR, with correction, on both eyes * Refractive error between -10 and +5 diopters, on both eyes Exclusion Criteria Healthy Volunteers: * Known ophthalmological, neurological or vestibular disease * Current medication/drugs that could potentially influence performance in ocular motor tasks and/or compliance in the judgement of the investigator (e.g. benzodiazepines, alcohol, or stimulants) * Stimulative medication (e.g. with Ritalin®) * Known substance abuse Inclusion Criteria Patients: * Age \> 3 * Informed consent by participant and/or legal representative, designated trusted person or next of kin, documented per signature * Refractive error between -10 and +5 diopters, on both eyes * Known ophthalmological or neurological disease Exclusion Criteria Patients: * Visual acuity in one or both eyes \< +1.3 LogMAR * Incapacity to understand and comply with the examination in the opinion of the investigator (e.g. due to very advanced dementia, with failure to comply with easy experimental instructions and tasks) * Known substance abuse

Primary outcome measure(s)

  • Normative Datasets — Single study visit - Day 0
    The primery outcome of this post-market clinical investigation is not the testing of a hypothesis, but the collection of normative data for the diagnositic system neos™. Normative datasets consisting of Demographic information (age and sex, ethnicity) neos™ output data, i.e. the neos™ report, including the measurement data used to generate the report and data logs generated during the examination.

Trial sites (3)

FacilityCityRegionStatus
machineMD AG Bern Canton of Bern Recruiting
Inselspital, Bern university hospital Bern Canton of Bern Recruiting
Onovis Augenpraxis Bern Canton of Bern Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07258212 on ClinicalTrials.gov ↗ ← All trials in Switzerland